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Background: The chemokine receptor CXCR4 (a receptor for the Cys-X-Cys
class of chemokines) is a CD4-associated coreceptor for T-cell-tropic strains of
human immunodeficiency virus 1 (HIV-1) and represents a target for antiviral
therapy. Infection by T-tropic HIV-1 can be blocked by stromal-cell-derived
factor-1 (SDF-1), the natural ligand of CXCR4. The broad variety of cells
expressing CXCR4 and the perturbations observed in mice deficient for SDF-1
suggest that antiviral compounds antagonizing the signalling activity of CXCR4
might have severe side effects in vivo. Compounds that interfere selectively
with HIV entry and not with SDF-1 signalling would therefore be useful.
Results: A series of peptides, each of 13 residues, spanning the whole SDF-1α
sequence were tested for their ability to block HIV-1 infection. The antiviral and
signalling properties of SDF-1 were retained by a peptide corresponding to its
amino terminus. Removal of the first two residues resulted in an antiviral
antagonist of the SDF-1–CXCR4 signalling pathway. We prepared 234 single-
substitution analogues and identified one antiviral analogue that had drastically
reduced agonistic or antagonistic properties. The antiviral peptides competed
with the monoclonal antibody 12G5 for CXCR4 binding. Their antiviral activity
seems to be due to receptor occupancy rather than induction of receptor
endocytosis.
Conclusions: The amino terminus of the SDF-1 chemokine is sufficient for
signal transduction via CXCR4 and for inhibition of HIV-1 entry, but these
activities could be dissociated in a peptide analogue. This peptide represents a
lead molecule for the design of low molecular weight antiviral drugs.
Background
Expression of the chemokine receptors CCR5 (a receptor
for the Cys-Cys class of chemokines) or CXCR4 (a recep-
tor for the Cys-X-Cys class of chemokines) in CD4+ cells
allows these cells to be infected by the human immunod-
eficiency virus 1 (HIV-1). CCR5 and CXCR4 can inter-
act with the HIV-1 envelope protein gp120 in the
presence of CD4, suggesting that they behave as CD4-
associated coreceptors for HIV-1 (reviewed in [1]). A
similar coreceptor activity has been reported for several
other G-protein-coupled receptors [2], but it is not clear
whether these receptors can be used by HIV-1 in vivo.
Whereas CCR5 is used as a coreceptor by most primary
HIV-1 strains, in particular macrophage (M)-tropic
strains, CXCR4 is used by the T-tropic subset of primary
HIV-1 strains, which replicate in CD4+ lymphocytes and
in T-cell lines [1]. T-tropic strains are generally isolated
at late stages of HIV-1 infection, and their emergence
has been proposed to play a role in the progression
towards AIDS [3,4]. A therapeutic benefit could there-
fore be expected from compounds inhibiting the core-
ceptor function of CXCR4. Also, because only a few
mutations in gp120 are required for HIV-1 to switch from
M tropism to T tropism [5–7], blocking the CCR5 core-
ceptor alone might favor the emergence of strains using
CXCR4. It seems, therefore, that both coreceptors
should be targeted by antiviral strategies aimed at block-
ing HIV-1 entry.
Stromal-cell-derived factor-1 (SDF-1) [8,9], a member of
the Cys-X-Cys chemokine family, mediates an intracellu-
lar Ca2+ rise and chemotaxis in CXCR4+ cells and is the
only known ligand for CXCR4 [10,11]. The 67 amino-acid
form of SDF-1 (SDF-1α) was found to block infection by
T-tropic HIV-1 [10,11], both by preventing a functional
interaction between CXCR4 and gp120 and by inducing
CXCR4 endocytosis [12]. In order to obtain leads for the
design of small molecular weight compounds to block the
HIV-1 coreceptor activity of CXCR4, we have screened
peptides derived from SDF-1α for their antiviral activity.
Furthermore, as antiviral compounds interfering with the
CXCR4 signalling pathway might be detrimental in vivo,
we have analyzed the signalling properties of SDF-1-
derived antiviral peptides.
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Results
Identification of a SDF-1-derived peptide retaining antiviral
activity
The human SDF-1α sequence was synthesized as tride-
capeptides that overlapped each other by 10 residues
(pepscan) by microsynthesis on cellulose membranes
[13,14]. Peptides were screened in a rapid semi-quantita-
tive assay based on the single-round infection of CD4+
HeLa P4.2 cells [15] by the HIV strain HIV-1 NDK [16].
This initial experiment revealed antiviral activity for pep-
tides from the amino-terminal region of SDF-1, in particu-
lar the peptide KPVSLSYRCPCRF (in single-letter
amino-acid code), corresponding to amino-acid residues
1–13 in SDF-1α (Figure 1a). The optimal and minimal
sizes required for antiviral activity were defined in a set of
peptides obtained by progressive shortening of the
sequence KPVSLSYRCPCRFFES, corresponding to
residues 1–16 of SDF-1 (Figure 1b). Four peptides had a
higher antiviral activity than peptide 1–13. Two of them,
including the most active peptide, VSLSYRCPCRFF
(residues 3–14), had two phenylalanine residues (F13 and
F14) at their carboxyl terminus. These residues were not
present in the shortest antiviral peptide, LSYRCPCR
(residues 5–12), however, and seemed dispensable for the
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Inhibition of HIV-1 infection by SDF-1-derived peptides. HeLa P4.2
cells were infected in 96-well trays with HIV-1 NDK in the presence of
the indicated peptides, and stained with X-Gal 24 h later. (a) Activity of
13-mer peptides spanning the whole sequence of mature human 
SDF-1α with an overlap of 10 residues between successive peptides.
The number of infected cells (stained blue) per well in one experiment
is shown. Peptides were synthesized on cellulose spots, and the whole
amount was used for one well (maximal concentration 300 µM).
Cys–Cys bridges are indicated by lines on the SDF-1α sequence.
(b) Activity of peptides derived from region 1–16 of SDF-1α by
progressive deletion. Peptides were synthesised on cellulose spots,
and used at ~30 µM. Bars represent infectious titres in cells treated
with peptide, relative to untreated HIV-infected cells (~3500 infected
cells per well). Error bars show the range of measures in duplicate
wells. (c) Dose-response experiments evaluating the IC50 values of
selected peptides prepared on a large scale. The IC50 values were
calculated as the mean of duplicate wells using different stock
solutions of the same peptide ± SD.
antiviral activity. The four amino-terminal residues of
peptide 1–13 also seemed dispensable for antiviral activity.
Dose-response experiments performed with selected pep-
tides revealed 50% HIV-1 inhibitory concentrations (IC50)
in the range of 10–25 µM (Figure 1c), confirming the con-
clusions drawn from the semi-quantitative pepscan experi-
ments. The antiviral activities of the peptides determined
with HIV-1 NDK extended to all other HIV-1 strains
tested (HIV-1 LAI, HIV-1 NY5, HIV-1 GUN and HIV-
1 89.6), with similar IC50 values being obtained (data not
shown). The slight antiviral effect of peptides representing
the carboxyl terminus of SDF-1α observed in this experi-
ment was not reproducible in dose-response experiments.
Identification of key residues for antiviral activity
In order to identify the key residues for the HIV-1
inhibitory activity in the sequence KPVSLSYRCPCRF
(peptide 1–13), each residue was exchanged for all other
amino acids, excluding cysteine. The ability of these pep-
tides to block HIV-1 NDK infection was compared with
that of the wild-type peptide (Figure 2a). In accordance
with our previous observations, the core sequence respon-
sible for the antiviral activity appeared to start at the
leucine residue L5. The core sequence is composed of
two groups of residues that cannot be randomly
exchanged for other amino acids without loss of antiviral
activity. The first stretch, formed by residues LSY (at
positions 5–7), and the second, formed by residues PCR
(positions 10–12), are separated by arginine and cysteine
residues (R8 and C9) that are apparently less important for
antiviral activity. Interestingly, the exchange of residue C9
for any aromatic amino acid resulted in peptides with
higher antiviral activity. The relative importance of
phenylalanine residue F13 was in agreement with previ-
ous observations (Figure 1b). Dose-response experiments
performed with selected peptides confirmed that certain
amino-acid substitutions increased the antiviral activity of
peptide 1–13 (Figure 2b). Moreover, both peptide 1–13
and one selected peptide analogue (KPVSHSYRCPCRF)
were able to block HIV-1 NDK infection of U373CD4+
cells stably expressing CXCR4, but were not able to block
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Figure 2
Inhibition of HIV infection by analogues derived from an SDF-1
peptide. (a) Antiviral activity of 234 analogues derived from the
KPVSLSYRCPCRF sequence (SDF-1 residues 1–13) by substituting
each residue for other amino acids, as indicated (columns). All
peptides were produced by microsynthesis on cellulose spots and
tested in the same experiment, including the parental sequence as a
control which was synthesised and tested 13 times (wt; upper row).
For each analogue, the same fraction of the synthesis was added to
the culture medium and HIV-1 infectivity tested as described in
Figure 1. This amount of parental peptide yielded an approximate 50%
reduction of the infectious titres (that is, 600 infected cells per well,
compared with 1200 infected cells per well for untreated cells). The
antiviral activity of the analogues is represented by shading from black
to white, as indicated. Darker shading corresponds to peptides with
antiviral activity lower than the parental peptide, lighter shading
corresponds to peptides blocking infection more efficiently than the
parental peptide. One of two representative experiments is shown.
Repeated pepscan with selected peptides gave similar results.
(b) Dose-response experiments evaluating IC50 values of peptide
1–13 and the selected analogues C9W, R10W and L5H synthesized
on a larger scale. Results are presented as in Figure 1c.
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cells expressing CCR5 from being infected by the M-
tropic strain HIV-1 YU2 (data not shown).
Mechanism of antiviral activity
To clarify the mechanism by which the peptides inhibited
HIV-1 entry, we analyzed their ability to induce CXCR4
internalization in the T-cell line CEM. After incubation at
37°C with peptides or with full-length SDF-1, cells were
stained with the anti-CXCR4 monoclonal antibody 12G5
[17] and analyzed by flow cytometry. A dose-dependent
downregulation of CXCR4 was observed upon treatment
of cells with SDF-1, as expected; downregulation was also
observed with peptide 1–13, but at markedly higher
peptide concentrations (Table 1). Peptides VSLSYR-
CPCRFF (residues 3–14) and LSYRCPCRFF (residues
5–14) induced significant downregulation of CXCR4
expression only at 100 µM, whereas they both inhibited
HIV-1 entry at lower concentrations (Figure 1c). Overall,
the ability of peptides to induce CXCR4 downregulation
did not seem to correlate with their antiviral activity. In
contrast, in direct competition assays, the binding of anti-
body 12G5 to CEM cells at 4°C was markedly reduced in
the presence of peptide 1–13 and peptide 5–14 at concen-
trations within the range of their IC50 values (Table 2);
similar results were obtained with HeLa CCR5+ cells, in
which the peptides competed with 12G5 for binding but
not with an anti-CCR5 antibody (data not shown). Com-
petition with 12G5 was more efficient for peptide 5–14,
which has the lower IC50 value (Figure 1c). These experi-
ments suggest that the antiviral activity of the SDF-1 pep-
tides is mainly due to CXCR4 occupancy, rather than to
the induction of CXCR4 endocytosis.
Signalling activities of different SDF-1 amino-terminal
peptides
Given that antiviral peptides interact with CXCR4, they
might interfere with its signalling activity. In CXCR4-
expressing cells, such as HeLa cells, binding of SDF-1
results in an intracellular Ca2+ rise [10]. This Ca2+ rise was
also observed after treatment of the cells with the antiviral
peptide 1–13 at micromolar concentrations (Figure 3b).
Treatment with peptide 1–13 abolished the Ca2+ response
of cells to a subsequent stimulation by 50 nM SDF-1. Since
the peptide was washed off the cells prior to SDF-1 addi-
tion, the lack of a Ca2+ response was probably due to desen-
sitization of CXCR4. Conversely, SDF-1 stimulation prior
to peptide addition abrogated the peptide-induced signal
(Figure 3a), indicating that the peptide and chemokine
bind to the same receptor, namely CXCR4. This peptide
thus behaved as an agonist rather than an antagonist of
CXCR4. Peptides lacking the amino-terminal lysine and
proline residues (K1 and P2), in particular peptide 3–14,
failed to induce a Ca2+ response, indicating a key role for
the K1 and P2 residues for signalling via CXCR4, although
peptide 3–14 did appear to induce CXCR4 desensitization
(Figure 3c). An analogue of peptide 1–13, bearing a leucine
to histidine substitution at position 5 (L5H), did not induce
a Ca2+ response in CXCR4+ cells (Figure 3d), showing that
the K1 and P2 residues are only part of a larger sequence
required for signalling via CXCR4. Given that the peptide
372 Current Biology, Vol 8 No 7
Table 1
Downregulation of surface-expressed CXCR4 by SDF-1 and
SDF-1-derived peptides.
Concentration (µM) Mean fluorescence
intensity (%)
SDF-1 100 ND
20 ND
4 ND
0.8 ND
0.2 23
KPVSLSYRCPCRF (1–13) 100 30
20 43
4 52
0.8 65
0.2 ND
VSLSYRCPCRFF (3–14) 100 31
20 75
4 84
0.8 93
0.2 ND
LSYRCPCRFF (5–14) 100 25
20 73
4 79
0.8 97
0.2 ND
Mean fluorescence intensity as compared with CXCR4 surface
expression on CEM cells in the absence of preincubation with SDF-1
or SDF-1-derived peptides. ND indicates not determined.
Table 2
Reduction of 12G5 binding by competition with SDF-1 and
SDF-1-derived peptides.
Concentration (µM) Mean fluorescence
intensity (%)
SDF-1 0.5 7
0.1 21
0.02 56
0.01 79
KPVSLSYRCPCRF (1–13) 100 13
20 56
5 88
1 104
LSYRCPCRFF (5–14) 100 12
20 13
5 38
1 84
Mean fluorescence intensity as compared with binding of antibody
12G5 to CEM cells in the absence of SDF-1 or SDF-1-derived
peptides. 
analogue L5H blocked HIV-1 entry more efficiently than
any other peptide tested, its lack of signalling activity was
unlikely to result from a lower affinity for CXCR4.
Remarkably, treatment of cells with peptide analogue L5H
did not significantly affect their response to subsequent
stimulation by SDF-1 (Figure 3d). In order to compare
further the signalling activity of these peptides, we tested
different concentrations of peptide 1–13 and peptide ana-
logue L5H and recorded their signalling activity as well as
their inhibitory effect on subsequent SDF-1 signalling in
the continued presence of the peptide. These titrations
revealed that peptide analogue L5H did not induce sig-
nalling at concentrations of 100 µM (Figure 4a), and that its
capacity to reduce subsequent SDF-1 stimulation was
markedly reduced compared to the wild-type peptide 1–13
at concentrations of 50 µM (Figure 4b; a reduction of the
SDF-1 signal by 20–50% was observed for both peptides at
doses even lower than 1 µM and might represent back-
ground inhibition rather than specific properties of the pep-
tides). It should be recalled in this context that peptide
analogue L5H blocked HIV infection with an IC50 value of
4 µM (Figure 2b). Peptide analogue L5H therefore appears
to selectively block the HIV-1 coreceptor activity of
CXCR4 without significantly interfering with its signalling
function. This property was unique to the L5H analogue,
because analogues C9W and P10W behaved in the same
way as the parental 1–13 peptide (data not shown).
Discussion
We have shown that peptides derived from the amino ter-
minus of the SDF-1 sequence retained both the ability to
interact with the CXCR4 receptor and the antiviral activ-
ity of the chemokine. Antiviral peptides encompassing the
entire amino-terminal sequence of SDF-1 induced sig-
nalling via CXCR4 followed by desensitization of the
receptor. Peptides lacking the amino-terminal residues K1
and P2, or bearing the L5H mutation, failed to elicit a
Ca2+ response. These findings are compatible with a pre-
vious report, in which synthetic SDF-1 lacking the five
amino-terminal amino-acid residues was devoid of antivi-
ral activity and failed to elicit an intracellular Ca2+ rise or
chemotactic responses in CXCR4-expressing cells [18].
Peptides with deletions at their amino termini interfered
with SDF-1 signalling despite being devoid of agonist
activity. This result is in accordance with the recent
description of full-length analogues of SDF-1, in which
the exchange of K1 and P2 with other amino acids results
in the generation of potent CXCR4 antagonists [19]. Most
interestingly, we found that the single L5H mutation dras-
tically reduced both the agonist activity of the peptide and
the interference with SDF-1 signalling. This analogue had
marked antiviral activity, however, that was superior to
wild-type peptides.
The importance of the amino terminus of a chemokine for
receptor recognition and cell activation is not without
precedent. The sequence motif ELR, which precedes the
Cys-X-Cys motif in the CXC chemokines that act on neu-
trophils, is essential for the binding and activation of both
interleukin-8 receptors, CXCR1 and CXCR2 ([20] and ref-
erences therein). The corresponding region in SDF-1 con-
sists of the LSY motif, which we found to be essential for
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Figure 3
Peptide-induced Ca2+ fluxes in CXCR4-
expressing cells. HeLa cells were sequentially
treated with SDF-1 (50 nM) and with the
indicated peptides (50 µM), or vice versa.
Cells were washed with buffer before the
second incubation. (a,b) Cross-inhibition
between the Ca2+ responses elicited by 
SDF-1 and by peptide KPVSLSYRCPCRF
(1–13). (c) Treatment with peptide
VSLSYRCPCRFF (3–14) does not induce a
Ca2+ response, neither does subsequent
treatment with SDF-1. (d) No Ca2+ response
is elicited after treatment with L5H (an
analogue of peptide 1–13) whereas a Ca2+
response is elicited after subsequent
treatment with SDF-1. Data from one
representative experiment out of three are
shown.
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HIV-1 inhibition. A two-site model derived from studies of
the interaction of the complement fragment C5a with its
receptor has been proposed for the interaction of
chemokines with their receptors [21,22]. In this model, an
initial interaction takes place between the compact core of
the chemokine and the amino terminus of the receptor (site
I), followed by the interaction of the flexible amino termi-
nus of the chemokine with site II, which is formed as a
pocket by extracellular loops and membrane-spanning
domains of the receptor. Interaction with site II leads to
receptor activation. Recent studies with chimeric α-
chemokines suggest that the amino terminus of SDF-1,
which precedes the Cys-X-Cys motif and is apparently
unstructured in solution, might engage a functional interac-
tion with site II, whereas residues 12–17 (termed the
RFFESH motif) are part of a structured loop and might
contribute to receptor recognition [19]. Our data suggest
that the SDF-1-derived peptides bind to site II, because
they were able to mediate receptor activation. Antagonist
peptides lacking the amino-terminal lysine and proline
residues may interfere with SDF-1 signalling by inducing
CXCR4 desensitization rather than by competing for recep-
tor binding. Similar observations have been reported previ-
ously for non-agonist ligands of the nicotinic receptor [23].
The L5H peptide analogue, however, has strongly reduced
signalling and desensitizing activities, because subsequent
addition of SDF-1 resulted in signal transduction. The
absence of the RFFESH motif in the small peptides might
result in a failure to interact with site I, the site of initial
receptor–chemokine interaction. Hence, the peptides could
be relatively easily replaced by the amino-terminal moiety
of SDF-1 after it has bound to the receptor via site I. 
The ability of SDF-1-derived peptides to induce CXCR4
endocytosis correlated with their capacity to induce signal
transduction, but did not correlate with their antiviral
properties. This suggests that infection is blocked by
mechanisms other than receptor endocytosis, possibly by
direct competition with the HIV envelope protein gp120
for CXCR4 occupancy. This assumption is reinforced by
the observation that SDF-1-derived peptides competed
directly with the anti-CXCR4 monoclonal antibody 12G5.
It cannot be excluded, however, that the binding of pep-
tides to CXCR4 induces an overall conformational change
affecting the ability of CXCR4 to bind gp120 and 12G5
but not SDF-1. In the context of chimeric human/rat
CXCR4, we found that the third extracellular domain
(loop 2) of the human receptor was part of the 12G5
epitope [24]. Given that SDF-1-derived peptides compete
for 12G5 binding and induce signalling, there seems to be
a close relationship between the third extracellular domain
of CXCR4 and site II. The 12G5 antibody blocks entry of
a variety of HIV-1 strains; it seems plausible that peptides
interfering with the 12G5 epitope might mask receptor
determinants required for HIV entry via CXCR4. This
assumption is in accordance with recent reports that other
compounds blocking HIV-1 entry via CXCR4 also block
12G5 binding [25,26].
Our findings showing that the antiviral activity of SDF-1
is not indissociably linked with its CXCR4-mediated sig-
nalling activity via CXCR4 and that an SDF-1-derived
peptide analogue can block HIV entry without markedly
antagonizing SDF-1 have implications for future drug
development. SDF-1-deficient mice have severe pertur-
bations in the development of the B-cell and myeloid lin-
eages and are not viable, suggesting an important function
of the chemokine as a homing factor in bone marrow [27].
Moreover, SDF-1 might have additional functions, for
example in T-cell homing and inflammatory processes,
given that CXCR4 is expressed by a broad variety of cells
[17] — a feature that seems unique amongst chemokine
receptors. Although individuals with a homozygous CCR-
5 deletion (∆CCR-5) show no apparent phenotype [28],
suggesting that CCR5 antagonists can be used in vivo,
interference with the CXCR4–SDF-1 pathway might lead
to severe side effects. Different inhibitors of HIV entry
via CXCR4 have recently been described [25,26,29]; all
proved to be antagonists of SDF-1, however.
A recent report showed that a common polymorphism in
the SDF-1 gene transcript correlated with the delayed
onset of AIDS in HIV-infected individuals, suggesting that
altered SDF-1 expression might prevent the emergence of
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Figure 4
Dose-response curves of SDF-1-derived peptides on Ca2+ flux and
SDF-1 response inhibition. (a) Signalling evoked by peptides
KPVSLSYRCPCRF (1–13) and KPVSHSYRCPCRF (L5H analogue) in
HeLa cells. Integration area of Ca2+ increase was measured for 2 min
after peptide application (n = 2). (b) Reduction of SDF-1 Ca2+
signalling by peptides KPVSLSYRCPCRF (1–13) and
KPVSHSYRCPCRF (L5H analogue). HeLa cells were incubated with
peptide for 3 min, SDF-1 was added (100 nM) and the integration area
of the Ca2+ response was measured for 2 min after chemokine
application (n = 2). The inhibition is represented as the percentage of
response to 100 nM SDF-1 in the absence of peptide.
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virus strains using CXCR4 as a coreceptor and thus prevent
rapid disease progression [30]. These data underline the
importance of CXCR4 as an HIV-1 entry cofactor in vivo
and thus reinforce the interest in the development of suit-
able agents to target this coreceptor.
Conclusions
Peptides derived from the amino terminus of SDF-1
retain both the ability to interact with CXCR4 and the
antiviral property of the chemokine. These activities can
be dissociated; removal of the amino-terminal residues
K1 and P2 results in peptides that do not induce sig-
nalling via CXCR4 but that do desensitize the receptor.
The L5H analogue of the peptide, encompassing the first
13 residues of SDF-1 and containing a leucine to histi-
dine substitution, does not induce either significant sig-
nalling or desensitization of CXCR4, but does retain
antiviral activity (IC50 = 4 µM) superior to wild-type pep-
tides. The antiviral activity is due to receptor occupancy
rather than to receptor internalization. The identification
of a non-agonistic, non-antagonistic antiviral peptide ana-
logue opens new avenues for the future design of small
molecular weight antiviral drugs that have selective
inhibitory activities against HIV but do not interfere with
CXCR4 signalling. 
Materials and methods
Peptide synthesis
Peptide scans and substitution analogues were prepared by spot syn-
thesis as described [13,14]. After synthesis and cleavage of the pro-
tection groups, the peptides were released from the cellulose support
as carboxamides by ammonia vapour. While still adsorbed to the mem-
brane, the spots (0.25 cm2) were punched out and transferred to wells
of microtiter plates. Each spot contained roughly 30 nmol peptide.
Larger amounts of selected peptides used in the dose-response exper-
iments were prepared on a multiple peptide synthesizer (Abimed)
according to the standard Fmoc machine protocols. These peptides
were purified to greater than 95% and characterized by MALDI-TOF
mass spectrometry. Peptides attached to cellulose discs were dis-
solved in water and added to cell culture at a final concentration of
approximately 30 µM, except for the initial pepscan experiment
(Figure 1a), in which the whole quantity of peptide was dissolved in
complete DMEM and used for one microtiter well. For dose-response
experiments, peptide stock solutions (2 mM) were prepared in water
and diluted into complete DMEM to the final concentration as indi-
cated. Correspondence concerning peptides and peptide design
should be addressed to J.S-M.
Infection assays
HIV-1 infectivity was scored using the CD4+ HeLa P4.2 cell line [15],
which is stably transfected with a lacZ reporter gene inducible by the
viral protein Tat. HIV-infected cells can therefore be detected by virtue
of their high level of β-galactosidase activity, yielding a blue staining in
the presence of the 5-bromo-4-chloro-3-indoyl-D-galacto-pyranoside
(X-Gal) substrate. Unless otherwise indicated, the HIV-1 NDK strain
[16] (subtype D) was used for all infection assays. Viral stocks were
supernatants of chronically infected CEM cells with infectious titers in
the range of 105–106 units/ml. For infections, HeLa P4.2 cells were
seeded in 96-well trays (1 × 104 cells per 100 µl per well) in DMEM
with 10% fetal calf serum and allowed to adhere overnight. The super-
natant was replaced by an equivalent volume of medium containing
virus (1–4 × 103 infectious units per well as indicated) and peptide as
indicated. Cells were fixed in 0.5% glutaraldehyde 24 h later, and
stained with X-Gal, as described [31]. Blue-stained cells were scored
under 20× magnification. Control experiments were performed using
the astroglioma cell line U373CD4+LTRlacZ stably expressing either
CXCR4, or CCR5 bearing a Myc tag at its amino terminus, using the
same procedure. The CCR5+ clone was infected with the HIV-1 YU2
isolate produced by HeLa cells transfected with proviral DNA.
CXCR4 downregulation
Surface expression of CXCR4 in CEM cells was analyzed as described
[12]. Briefly, cells (5 × 105) were incubated for 40 min at 37°C with
either SDF-1, peptides, or medium alone. The cells were then washed
with an acidic glycine buffer, incubated at 4°C with 12G5 monoclonal
antibody and subsequently labelled with a phycoerythrin (PE)-conju-
gated secondary antibody (Southern Biotechnology). After staining,
cells were fixed in 1% paraformaldehyde and CXCR4 expression was
analyzed with a FACScan cytofluorometer (Becton Dickinson).
Competition of peptides with 12G5
To detect competition for CXCR4 binding, peptides or SDF-1, together
with 12G5 antibody (6 µg/ml) were added simultaneously to 1 × 106
CEM cells. After 45 min on ice, cells were washed, stained with a PE-
conjugated secondary antibody (DAKO) and analyzed by flow cytome-
try as described [24]. Control experiments were performed on HeLa
CCR5+ cells using either 12G5 or 2D7 (anti-CCR5, obtained from the
NIH AIDS Reagent Program) antibodies.
Intracellular calcium measurements
HeLa cells were loaded with the fluorescent dye fura-2 (3 µM) in mam-
malian saline buffer (140 mM NaCl, 5 mM KCl, 10 mM HEPES pH 7.4,
1 mM CaCl2, 1 mM MgCl2) for 30 min at room temperature. The same
buffer was used to wash the cells before the addition of SDF-1 or pep-
tides at the indicated concentrations. Single-cell Ca2+ measurements
were made at 37°C with a Nikon Diaphot 300 microscope and an
IMSTAR imaging system (Paris) as described [32]. Fura-2 fluores-
cence was excited alternatively at 380 nm and 350 nm. Four images
were averaged at each wavelength and one Ca2+ image was generated
every 6 sec.
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